194 related articles for article (PubMed ID: 17906988)
1. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review.
Bien E; Balcerska A
Biomarkers; 2008 Feb; 13(1):1-26. PubMed ID: 17906988
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.
El Houda Agueznay N; Badoual C; Hans S; Gey A; Vingert B; Peyrard S; Quintin-Colonna F; Ravel P; Bruneval P; Roncelin S; Lelongt B; Bertoglio J; Fridman WH; Brasnu D; Tartour E
Clin Exp Immunol; 2007 Oct; 150(1):114-23. PubMed ID: 17680822
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma.
Gupta M; Stenson M; O'Byrne M; Maurer MJ; Habermann T; Cerhan JR; Weiner GW; Witzig TE
Ann Oncol; 2016 Jan; 27(1):165-72. PubMed ID: 26487586
[TBL] [Abstract][Full Text] [Related]
4. Serum level of soluble interleukin-2 receptor alpha correlates with the clinical course and activity of Wilms' tumour and soft tissue sarcomas in children.
Bien E; Balcerska A; Kuchta G
Biomarkers; 2007; 12(2):203-13. PubMed ID: 17536769
[TBL] [Abstract][Full Text] [Related]
5. Serum concentrations of soluble interleukin-2 receptor in patients with malignant brain tumors.
Yoshida S; Morii K
J Surg Oncol; 2000 Oct; 75(2):131-5. PubMed ID: 11064393
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin's lymphoma.
Jo SA; Hwang SH; Chang CL; Kim SY; Shin HJ; Chung JS; Sol MY; Lee EY
Korean J Lab Med; 2010 Dec; 30(6):600-5. PubMed ID: 21157146
[TBL] [Abstract][Full Text] [Related]
7. Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia.
Lange BJ; Yang RK; Gan J; Hank JA; Sievers EL; Alonzo TA; Gerbing RB; Sondel PM
Pediatr Blood Cancer; 2011 Sep; 57(3):398-405. PubMed ID: 21681921
[TBL] [Abstract][Full Text] [Related]
8. Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma.
Yang ZZ; Grote DM; Ziesmer SC; Manske MK; Witzig TE; Novak AJ; Ansell SM
Blood; 2011 Sep; 118(10):2809-20. PubMed ID: 21719603
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma.
Wang LS; Chow KC; Li WY; Liu CC; Wu YC; Huang MH
Clin Cancer Res; 2000 Apr; 6(4):1445-51. PubMed ID: 10778976
[TBL] [Abstract][Full Text] [Related]
10. Increased serum-soluble interleukin-2 receptor in burn patients: characterization and effects on the immune system.
Jobin N; Garrel D; Bernier J
Hum Immunol; 2000 Mar; 61(3):233-46. PubMed ID: 10689113
[TBL] [Abstract][Full Text] [Related]
11. Soluble cytokine receptors (sIL-2Rα, sIL-2Rβ) induce subunit-specific behavioral responses and accumulate in the cerebral cortex and basal forebrain.
Zalcman SS; Patel A; Mohla R; Zhu Y; Siegel A
PLoS One; 2012; 7(4):e36316. PubMed ID: 22558434
[TBL] [Abstract][Full Text] [Related]
12. The fractional excretion of soluble interleukin-2 receptor-alpha is an excellent predictor of the interleukin-2 receptor-alpha status after treatment with daclizumab.
ter Meulen CG; Jacobs CW; Wetzels JF; Klasen IS; Hilbrands LB; Hoitsma AJ
Transplantation; 2004 Jan; 77(2):281-6. PubMed ID: 14742994
[TBL] [Abstract][Full Text] [Related]
13. Increased sIL-2Rα leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients
Long D; Yu S; Zhang L; Guo Y; Xu S; Rao Y; Huang Z; Luo Q; Li J
Front Immunol; 2022; 13():938556. PubMed ID: 36203602
[TBL] [Abstract][Full Text] [Related]
14. G-CSF therapy and catheter-related Gram-positive sepsis increase serum IL-2 receptor α level and may falsely suggest a relapse in children with soft tissue sarcomas unless serum beta2-microglobulin, lactate dehydrogenase and C-reactive protein levels are determined concomitantly.
Bien E; Balcerska A; Niedzwiecki M; Krawczyk M; Rapala M; Trzonkowski P; Stepinski J
Cytokine; 2011 Sep; 55(3):347-52. PubMed ID: 21640605
[TBL] [Abstract][Full Text] [Related]
15. Serum level of soluble interleukin-2 receptor correlates with CD25 expression in patients with T lymphoblastic lymphoma.
Toji T; Takata K; Sato Y; Miyata-Takata T; Hayashi E; Habara T; Maeda Y; Tanimoto M; Yoshino T
J Clin Pathol; 2015 Aug; 68(8):622-7. PubMed ID: 25935549
[TBL] [Abstract][Full Text] [Related]
16. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
17. Use of an antibody against the soluble interleukin 2 receptor alpha subunit can modulate the stability and biodistribution of interleukin-2.
Kobayashi H; Tagaya Y; Han ES; Kim IS; Le N; Paik CH; Pastan I; Nelson DL; Waldmann TA; Carrasquillo JA
Cytokine; 1999 Dec; 11(12):1065-75. PubMed ID: 10623432
[TBL] [Abstract][Full Text] [Related]
18. IL-15 induces the release of soluble IL-2Ralpha from human peripheral blood mononuclear cells.
Treiber-Held S; Stewart DM; Kurman CC; Nelson DL
Clin Immunol Immunopathol; 1996 Apr; 79(1):71-8. PubMed ID: 8612353
[TBL] [Abstract][Full Text] [Related]
19. Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogenic bone marrow transplantation.
Foley R; Couban S; Walker I; Greene K; Chen CS; Messner H; Gauldie J
Bone Marrow Transplant; 1998 Apr; 21(8):769-73. PubMed ID: 9603399
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor.
Wang L; Liao DZ; Zhang J; Xia ZJ; Peng XW; Lu Y
Med Oncol; 2013 Dec; 30(4):723. PubMed ID: 24037346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
